8:25 am Chair’s Opening Remarks

Examining IPF Clinical Trial Design to Expand Therapeutic Development for ILDs

8:30 am Identifying & Highlighting Differences Between IPF & PPF to Inform Future Clinical Trial Endpoints

  • Anna Podolanczuk Assistant Professor - Pulmonary & Critical Care Medicine, Weill Cornell - Cornell University


  • Understanding how endpoints differ for studies of progressive pulmonary fibrosis in comparison to IPF to navigate trial design

9:00 am Adapting Clinical Trial Design & Endpoints for ILD Therapeutic Development: Harnessing Digital Health Technology (DHT) Endpoints


  • Selecting and expanding the ILD patient population
  • Adapting clinical trials using digital health technology to facilitate remote monitoring of patients health status
  • Incorporating the patient perspective into clinical trial design
  • Assessing digital endpoints across fibrotic ILDs studies

9:30 am Roundtables: Navigating PPF Inclusion Criteria for Clinical Trial Design: Do We Include Only Specific Progressive Fibrosis?


To consider the patient population and other considerations of inclusion and exclusion criteria in therapeutic development

– PPF trial design vs. IPF trial design

– PPF trial design vs ILD trial design

– IPF trial design vs ILD trial design

Harnessing a Combination of Preclinical Models to Effectively Predict ILD Therapeutic Efficacy

10:00 am Transitioning Inhaled Preclinical Studies to the Clinic: Development of PRS-220, an Inhaled Anticalin Protein targeting CTGF/CCN2 for the Treatment of Lung Fibrosis


  • Highlighting benefits of local intervention via inhalation versus systemic administration of drugs
  • Using inhaled Anticalin proteins as a novel class of biotherapeutics for respiratory disease
  • Illuminating the development and preclinical characterization of PRS-220, a novel inhaled CTGF inhibitor, that is in clinical development for the treatment of lung fibrosis

10:30 am Morning Break

11:30 am Using a Combination of Preclinical Models: The Way Forward for Mechanisms – Based Clinical Translation

  • Satish Madala Professor & Basic Science Director, University of Cincinnati


  • Understanding which models suitably predict translatability to the clinic
  • Navigating the therapeutic window when variability is high with a comprehensive set of preclinical studies
  • Exploring preclinical modelling across ILDs to transition from IPF to ILD indications
  • Harnessing computerized approaches to access laboratory and preclinical data to cut costs and therapeutic development time
  • Understanding cellular and molecular mechanisms underlying progressive fibrosis in ILDs
  • Limiting exposure to the lungs to reduce systemic side effects

12:00 pm Exploring the Consistency of Readouts Across Preclinical Models to Evaluate the Use of Novel Fibrosis Models in Preclinical Therapeutic Development


  • Implementing precision cut lung slices and 3D tissue models in conjunction with the bleomycin model to attain therapeutic confidence
  • Harnessing artificial intelligence in preclinical development
  • Using CT scans as a biomarker of therapeutic efficacy
  • Looking to the future of ILD preclinical research – what should be implemented to improve the robustness of therapeutics moving into the clinic?

12:30 pm Lunch

Applying a Precision Medicine Approach to Select & Personalize Therapies for PPF & ILDs

1:30 pm Engineering 3D Lung Models for Drug Discovery and Validation


  • Highlighting a bottomup approach for modeling pulmonary fibrosis
  • Exploring cell-cell and cell-microenvironment interactions in the lung
  • Harnessing the model to explore therapeutic efficacy and the chemical cues of fibrosis

2:00 pm Reversing Translational Efforts to Identify New Pathways Contributing to ILD-Expanding the gp130-Dependent Cytokine Axis


  • Analyzing the fibrotic pathways to understand the fibrotic pathways across ILDs
  • Treating both the fibrotic features and inflammatory features of CT-ILDs to improve therapeutic outcomes
  • Discussing novel and/or additional development pathways in IPF and ILD to shine a spotlight on innovative therapeutic development

2:30 pm Oligonucleotides as Potential Therapies for Pulmonary Fibrosis


  • Discussing the unmet clinical need for pulmonary disease treatment which could be targeted using oligonucleotide therapies
  • Considering the biological barriers and challenges with delivering oligonucleotide therapies to the lung and potential solutions
  • Examining the potential delivery methods to pulmonary tissue and utilization of different routes of administration when investigating oligonucleotide therapies for the lung

3:00 pm Roundtable Discussions: Evaluating the Potential of Immunosuppressive & Antifibrotic Combinational Strategies for ILD Precision Medicine


This is your opportunity to join the immersive and interactive discussions on your round table to evaluate immunosuppressive and antifibrotic therapeutics for CT-ILD and PPF precision medicine. Looking to the future for

personalized medicines for patients in need

3:30 pm Chair’s Closing Remarks